SCHEMBL2775968

SCHEMBL2775968

Cc1c2ccc(=O)cc-2oc2cc(O)ccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 3/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
POLB P06746 2/20 0.63
ATM Q13315 1/20 0.63
PLEC Q15149 1/20 0.63
HSD17B3 P37058 6/20 0.59
ESR1 P03372 3/20 0.56
ESR2 Q92731 3/20 0.56
L3MBTL1 Q9Y468 1/20 0.54
CDC25A P30304 1/20 0.52
CDC25B P30305 1/20 0.52
CDC25C P30307 1/20 0.52
ALPL P05186 1/20 0.52
ALPI P09923 1/20 0.52
ALPG P10696 1/20 0.52
GNG2 P59768 1/20 0.52
GNB1 P62873 1/20 0.52
HPGD P15428 3/20 0.50
KDM4E B2RXH2 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12909301 0.83 USP2 (0.68) USP2MEN1KMT2APOLBATM
SCHEMBL21151072 0.82 KMT2A (0.60) USP2MEN1KMT2APOLBATM
SCHEMBL13320808 0.81 KMT2A (0.59) USP2MEN1KMT2APOLBATM
SCHEMBL12679617 0.81 KMT2A (0.59) USP2MEN1KMT2APOLBATM
SCHEMBL14044262 0.81 USP2 (0.77) USP2MEN1KMT2APOLBATM
SCHEMBL10030600 0.80 USP2 (0.64) USP2MEN1KMT2APOLBATM
SCHEMBL5468848 0.80 USP2 (0.71) USP2MEN1KMT2APOLBATM
SCHEMBL8427558 0.79 USP2 (0.64) USP2MEN1KMT2APOLBATM
SCHEMBL16804613 0.79 KDM4E (0.56) USP2MEN1KMT2APOLBESR1
SCHEMBL12909281 0.79 USP2 (0.62) USP2MEN1KMT2APOLBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023235535-A1 FLUORESCENTLY-ACTIVE FREE RADICAL TAGS FOR SIMULTANEOUS GLYCAN QUANTITATION AND CHARACTERIZATION MONTCLAIR STATE UNIVERSITY (US) 2023-12-07 WO disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8748480-B2 Methods for treating opioid tolerance UNIVERSITY OF ROCHESTER (US) 2014-06-10 US disclosed
US-8748480-B2 Methods for treating opioid tolerance UNIVERSITY OF ROCHESTER (US) 2014-06-10 US disclosed
US-20130116313-A1 Compositions and Methods for Inhibiting G Protein Signaling UNIVERSITY OF ROCHESTER (US) 2013-05-09 US disclosed
US-20130116313-A1 Compositions and Methods for Inhibiting G Protein Signaling UNIVERSITY OF ROCHESTER (US) 2013-05-09 US disclosed
US-20130018195-A1 FLUORESCENT CELL MARKERS KODE BIOTECH LIMITED (NZ) 2013-01-17 US disclosed
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US disclosed
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US disclosed
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US disclosed
EP-2147310-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING University of Rochester (US) 2010-01-27 EP disclosed
US-20090221691-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-09-03 US disclosed
US-20090221691-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-09-03 US disclosed
WO-2009020677-A9 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIV ROCHESTER (US) 2009-04-16 WO disclosed
WO-2009020677-A9 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIV ROCHESTER (US) 2009-04-16 WO disclosed
WO-2009020677-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-02-12 WO disclosed
WO-2009020677-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018195-A1 FLUORESCENT CELL MARKERS CD69, SPTLC2, CD4 USP2 1567/4885MEN1 1613/4885KMT2A 3566/4885
US-20130116313-A1 Compositions and Methods for Inhibiting G Protein Signaling GNAI3, GNAI1, GNAI2 USP2 2380/4885MEN1 2590/4885KMT2A 4380/4885
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING GNAI1, GNAI3, GNAI2 USP2 1478/4885MEN1 3515/4885KMT2A 4394/4885
US-20090221691-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING GNAI3, GNAI1, GNAI2 USP2 2364/4885MEN1 2570/4885KMT2A 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.